Barbara Walley

3.7k total citations
24 papers, 683 citations indexed

About

Barbara Walley is a scholar working on Cancer Research, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Barbara Walley has authored 24 papers receiving a total of 683 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Cancer Research, 14 papers in Pulmonary and Respiratory Medicine and 14 papers in Genetics. Recurrent topics in Barbara Walley's work include Estrogen and related hormone effects (14 papers), Breast Cancer Treatment Studies (13 papers) and Advanced Breast Cancer Therapies (11 papers). Barbara Walley is often cited by papers focused on Estrogen and related hormone effects (14 papers), Breast Cancer Treatment Studies (13 papers) and Advanced Breast Cancer Therapies (11 papers). Barbara Walley collaborates with scholars based in United States, Canada and Switzerland. Barbara Walley's co-authors include Olivia Pagani, Prudence A. Francis, Gini F. Fleming, Meredith M. Regan, Richard D. Gelber, Alan S. Coates, Marco Colleoni, Aron Goldhirsch, Carlo Tondini and Henry Gómez and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Barbara Walley

24 papers receiving 663 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Barbara Walley United States	13	436	391	249	186	91	24	683
D. Serin France	15	759 1.7×	375 1.0×	430 1.7×	127 0.7×	203 2.2×	73	1.2k
Marit Holmqvist Sweden	15	329 0.8×	293 0.7×	277 1.1×	93 0.5×	112 1.2×	19	766
Enrique Bargalló‐Rocha Mexico	18	478 1.1×	445 1.1×	181 0.7×	95 0.5×	69 0.8×	82	899
Nicola Roche United Kingdom	8	315 0.7×	285 0.7×	275 1.1×	68 0.4×	79 0.9×	18	629
Alice Zervoudakis United States	11	690 1.6×	320 0.8×	67 0.3×	133 0.7×	61 0.7×	34	851
Bastien Nguyen United States	13	454 1.0×	384 1.0×	116 0.5×	446 2.4×	37 0.4×	24	870
Katia Khoury United States	11	403 0.9×	217 0.6×	110 0.4×	133 0.7×	111 1.2×	31	725
Piero Fregatti Italy	13	212 0.5×	160 0.4×	59 0.2×	97 0.5×	105 1.2×	54	495
S. Jezdic Italy	9	316 0.7×	319 0.8×	91 0.4×	233 1.3×	110 1.2×	15	795
Rémy Largillier France	12	478 1.1×	314 0.8×	71 0.3×	144 0.8×	50 0.5×	32	728

Countries citing papers authored by Barbara Walley

Since Specialization

Citations

This map shows the geographic impact of Barbara Walley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barbara Walley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barbara Walley more than expected).

Fields of papers citing papers by Barbara Walley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barbara Walley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barbara Walley. The network helps show where Barbara Walley may publish in the future.

Co-authorship network of co-authors of Barbara Walley

This figure shows the co-authorship network connecting the top 25 collaborators of Barbara Walley. A scholar is included among the top collaborators of Barbara Walley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barbara Walley. Barbara Walley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Huober, J., Roswitha Kammler, Patrizia Dell’Orto, et al.. (2024). 109O Adjuvant endocrine therapy for premenopausal invasive lobular carcinoma (ILC): Results from SOFT and TEXT phase III studies. ESMO Open. 9. 103097–103097. 2 indexed citations

Pagani, Olivia, Prudence A. Francis, Gini F. Fleming, et al.. (2019). Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT. Journal of Clinical Oncology. 38(12). 1293–1303. 82 indexed citations

Regan, Meredith M., Prudence A. Francis, Olivia Pagani, et al.. (2018). Absolute improvements in freedom from distant recurrence with adjuvant endocrine therapies for premenopausal women with hormone receptor-positive (HR+) HER2-negative breast cancer (BC): Results from TEXT and SOFT.. Journal of Clinical Oncology. 36(15_suppl). 503–503. 12 indexed citations

Regan, Meredith M., Barbara Walley, Prudence A. Francis, et al.. (2017). Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT. Annals of Oncology. 28(9). 2225–2232. 47 indexed citations

Johansson, Harriet, Kathryn P. Gray, Olivia Pagani, et al.. (2016). Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial. Breast Cancer Research. 18(1). 110–110. 21 indexed citations

Regan, Meredith M., Prudence A. Francis, Olivia Pagani, et al.. (2016). Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer: TEXT and SOFT Trials. Journal of Clinical Oncology. 34(19). 2221–2231. 115 indexed citations

Lupichuk, Sasha, Lihong Zhong, Jenny J. Ko, et al.. (2015). Discharge to Primary Care for Survivorship Follow-Up: How Are Patients With Early-Stage Breast Cancer Faring?. Journal of the National Comprehensive Cancer Network. 13(6). 762–771. 9 indexed citations

Vallance, Jeff K., Christine M. Friedenreich, Nicole Culos-Reed, et al.. (2015). Exploring the Feasibility of a Broad-Reach Physical Activity Behavior Change Intervention for Women Receiving Chemotherapy for Breast Cancer: A Randomized Trial. Cancer Epidemiology Biomarkers & Prevention. 25(2). 391–398. 27 indexed citations

Goldhirsch, Aron, Richard D. Gelber, Prudence A. Francis, et al.. (2015). Abstract S3-08: Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Analysis of the SOFT trial. Cancer Research. 75(9_Supplement). S3–8. 4 indexed citations

10.

Bernhard, J., Weixiu Luo, Karin Ribi, et al.. (2014). Patient-reported endocrine symptoms, sexual functioning, and quality of life (QoL) in the IBCSG TEXT and SOFT trials: Adjuvant treatment with exemestane (E) plus ovarian function suppression (OFS) versus tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC).. Journal of Clinical Oncology. 32(15_suppl). 557–557. 10 indexed citations

11.

Collie, Kate, Amy Waller, Anna Taylor, et al.. (2014). Qualitative Evaluation of Care Plans for Canadian Breast and Head-and-Neck Cancer Survivors. Current Oncology. 21(1). 18–28. 19 indexed citations

12.

Pagani, Olivia, Meredith M. Regan, Barbara Walley, et al.. (2014). Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT trials.. Journal of Clinical Oncology. 32(15_suppl). LBA1–LBA1. 5 indexed citations

13.

Regan, Meredith M., Olivia Pagani, Gini F. Fleming, et al.. (2013). Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: Design of the TEXT and SOFT trials. The Breast. 22(6). 1094–1100. 56 indexed citations

14.

Shepherd, L. E., Karen A. Gelmon, Barbara Walley, et al.. (2012). Abstract P1-13-01: A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: Results of the final relapse free survival analysis.. Cancer Research. 72(24_Supplement). P1–13. 3 indexed citations

15.

Burnell, Margot J., Mark N. Levine, Judith‐Anne W. Chapman, et al.. (2009). Cyclophosphamide, Epirubicin, and Fluorouracil Versus Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel Versus Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Node-Positive or High-Risk Node-Negative Breast Cancer. Journal of Clinical Oncology. 28(1). 77–82. 112 indexed citations

16.

Regan, Meredith M., Olivia Pagani, Barbara Walley, et al.. (2008). Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?. Annals of Oncology. 19(7). 1231–1241. 39 indexed citations

17.

Bathe, Oliver F., S. Ernst, Francis Sutherland, et al.. (2005). A phase II study of neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for resectable liver metastases from colorectal cancer. Journal of Clinical Oncology. 23(16_suppl). 3662–3662. 3 indexed citations

18.

Chagpar, Anees B., et al.. (2004). The replication error phenotype is associated with the development of distant metastases in hormonally treated patients with breast carcinoma. Cancer. 100(5). 913–919. 7 indexed citations

19.

Reyno, Leonard, Lesley Seymour, Dongsheng Tu, et al.. (2004). Phase III Study of N,N-Diethyl-2-[4-(Phenylmethyl) Phenoxy]Ethanamine (BMS-217380-01) Combined With Doxorubicin Versus Doxorubicin Alone in Metastatic/Recurrent Breast Cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19. Journal of Clinical Oncology. 22(2). 269–276. 52 indexed citations

20.

Francis, Prudence A., et al.. (2003). Tailored treatment investigations for premenopausal women with endocrine responsive (ER+ and/or PGR+) breast cancer: The SOFT, TEXT, and PERCHE trials. The Breast. 12. S44–S44. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact